Today: 8 June 2026
Browse Category

NYSE:NUVB 19 November 2025 - 11 December 2025

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio shares surged nearly 200% year-to-date, trading around $7.84 on December 11, 2025, after FDA approval of its lung cancer drug IBTROZI and strong analyst upgrades. H.C. Wainwright raised its price target to $18, citing higher revenue forecasts and clinical results. Average daily volume reached 8.7 million shares. The company reported 204 new patients started IBTROZI in Q3.
11 December 2025
Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

Nuvation Bio shares surged about 50% to $7.20 in early afternoon trading Wednesday after B. Riley Securities initiated coverage with a “Buy” rating and $12 price target. The rally followed strong commercial results for lung cancer drug IBTROZI and coincided with management’s presentation at the Jefferies Global Healthcare Conference in London. Trading volume hit tens of millions of shares, lifting the company’s market cap to $2.4 billion.
19 November 2025
··

Stock Market Today

  • Indian Stock Market Surpasses Taiwan and South Korea Amid Tech Sell-Off
    June 8, 2026, 4:29 AM EDT. India's stock market capitalization climbed to $4.36 trillion, surpassing Taiwan and South Korea. This shift comes as major technology stocks, including Samsung Electronics, SK Hynix, and TSMC, faced a significant sell-off. The drop in tech shares impacted the market caps of Taiwan and South Korea, allowing India to reclaim its position. The movement reflects changing investor sentiment in Asia's key technology hubs and highlights India's growing market presence despite global tech sector volatility.

Latest articles

Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

8 June 2026
Eli Lilly closed at $1,131.42, up 0.55%, after releasing late-stage data showing its obesity drug retatrutide led to 28.3% weight loss over 80 weeks and reduced sleep apnea and knee pain, fueling hopes its obesity pipeline could expand beyond weight loss as rivals Boehringer Ingelheim and Zealand Pharma unveiled competing data, setting up a key test for Lilly’s trillion-dollar valuation as trading resumes.
SK Hynix Slips Even After Nvidia Deal as Korean AI Shares Slide

SK Hynix Slips Even After Nvidia Deal as Korean AI Shares Slide

8 June 2026
SK Hynix plunged 7.68% to 1,911,000 won despite sealing a multi-year Nvidia memory deal, as fears of a U.S. rate hike and a tech stock rout triggered circuit breakers and an 8.3% KOSPI crash, overshadowing strong AI demand and ongoing HBM supply constraints.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 08.06.2026

8 June 2026
LIVEMarkets rolling coverageStarted: June 8, 2026, 4:00 AM EDTUpdated: June 8, 2026, 4:29 AM EDT Indian Stock Market Surpasses Taiwan and South Korea Amid Tech Sell-Off June 8, 2026, 4:29 AM EDT. India’s stock market capitalization climbed to $4.36 trillion, surpassing Taiwan and South Korea. This shift comes as major technology stocks, including Samsung Electronics, SK Hynix, and TSMC, faced a significant sell-off. The drop in tech shares impacted the market caps of Taiwan and South Korea, allowing India to reclaim its position. The movement reflects changing investor sentiment in Asia’s key technology hubs and highlights India’s growing market presence
Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Go toTop